Dianthus Therapeutics (NASDAQ:DNTH) Hits New 52-Week High – Here’s What Happened

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) reached a new 52-week high during trading on Thursday . The company traded as high as $102.24 and last traded at $101.1490, with a volume of 69081 shares. The stock had previously closed at $98.07.

Wall Street Analyst Weigh In

DNTH has been the subject of a number of research analyst reports. Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Monday, April 20th. TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wedbush lifted their price target on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. Finally, William Blair reiterated an “outperform” rating on shares of Dianthus Therapeutics in a report on Monday, March 16th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $117.82.

Dianthus Therapeutics Stock Performance

The firm has a market cap of $5.34 billion, a P/E ratio of -23.63 and a beta of 1.20. The firm’s fifty day moving average price is $87.77 and its 200 day moving average price is $71.75.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.22. The company had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. As a group, analysts expect that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Simrat Randhawa sold 26,530 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the sale, the executive vice president directly owned 4,000 shares in the company, valued at $362,480. This represents a 86.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Adam M. Veness sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total value of $2,424,000.00. Following the sale, the senior vice president directly owned 30,000 shares in the company, valued at approximately $2,424,000. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 3.02% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. First Horizon Corp purchased a new stake in Dianthus Therapeutics during the first quarter valued at approximately $32,000. Caitong International Asset Management Co. Ltd purchased a new stake in Dianthus Therapeutics in the fourth quarter valued at about $40,000. Raymond James Financial Inc. acquired a new position in shares of Dianthus Therapeutics during the second quarter valued at about $27,000. Russell Investments Group Ltd. acquired a new position in shares of Dianthus Therapeutics during the third quarter valued at about $64,000. Finally, ABS Direct Equity Fund LLC purchased a new stake in Dianthus Therapeutics during the 1st quarter worth approximately $179,000. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.